ClearCut

Intraoperative MRI System

FOR EXCISED BREAST CANCER TISSUE

Our innovative MRI system provides immediate Intuitive visual display, allowing surgeons to ensure clear margins before patient closure.

Tell me more

Finally,

enhanced intraoperative clinical judgment for tumour margin detection.

In the OR

First and only mobile and compact MRI inside the operating room

Clear margins

Provides real time intraoperative margin assessment of excised tissue during breast-conserving cancer surgery

Simple and Intuitive

Easy-to-use system with clear, actionable results for surgeons.

Technology

ClearCoast empowers surgeons with real-time insights when they can still act, helping reduce residual cancer and the need for repeat surgery, giving patients a better start on their recovery journey.

Real-time DW-MRI system for excised breast tissue

The Challenge

  • During Breast-Conserving Surgery (BCS), surgeons lack reliable real-time information to determine whether all cancerous tissue has been removed.
  • The global re-excision (repeated surgeries) rate following BCS is estimated at approximately 25%, primarily due to positive surgical margins identified during postoperative pathological examination.
  • The need for additional surgery increases patient distress, prolongs treatment and recovery, and places a significant operational and financial burden on healthcare providers.

Diffusion-weighted magnetic resonance imaging (dw-MRI)

The Solution

  • ClearCoast™ is an innovative, portable, DW-MRI system (Diffusion-Weighted Magnetic Resonance Imaging) that performs real-time intraoperative margin assessment in excised breast tumors during Breast Conserving Surgery (BCS).
  • The ClearCoast™ system is considered a near-patient In-Vitro Diagnostic (IVD) system that performs ex-vivo scans outside the patient's body.
  • The system provides breast cancer surgeons with the ability to examine and indicate the margin status of the excised breast tissue and perform additional corrections during the surgical procedure, to reduce the re-excision rate.
Photographic image of a freshly excised, scanned inked specimen (left) and the corresponding ClearCoast™ diffusion-weighted map (right). The color code represents the degree of diffusion restriction. The red arrow points to an area of highly restricted diffusion, suspected as malignant tissue, on both images.

Photographic image of a freshly excised, scanned inked specimen (left) and the corresponding ClearCoast™ diffusion-weighted map (right). The color code represents the degree of diffusion restriction. The red arrow points to an area of highly restricted diffusion, suspected as malignant tissue, on both images.

Clinical Evidence

International clinical studies validate the ClearCoast™ technology and its high performance in real-world use.

↓80%

potential reduction in re-excision rates

400+

patients in international clinical trials

25%

typical re-excision rate without intraoperative assessment

3

studies across the US, Europe and Israel

About Us

ClearCut is at the forefront of medical technology, dedicated to revolutionizing breast cancer surgery. Our mission is to empower surgeons with real-time, actionable insights, drastically reducing the need for repeat surgeries and improving patient outcomes. We bring the power of MRI directly into the operating room, focusing on the excised tissue rather than the patient, which simplifies the process and enhances safety.

Founded on principles of innovation and clinical excellence, ClearCut's system is designed for ease of use and immediate interpretation. With successful clinical studies conducted across Europe and Israel, our technology is proven to deliver precise results, helping surgical teams make confident decisions during critical moments. We believe in providing tools that are not only advanced but also seamlessly integrate into existing surgical workflows.

Real-Time Imaging

Immediate visualization of excised tissue margins.

Enhanced Surgical Precision

Minimize re-excision rates and improve patient outcomes.

Safe & Non-Invasive

Ex-vivo application ensures no patient contact during imaging.

Clinically Validated

Proven success in studies across Europe and Israel.

Market

Expanding ClearCoast™ availability worldwide.

Europe Distribution

The CE-marked product is distributed in Europe by PFM Medical gmbh.

Rest of World

The company is looking for distributors that will expand its sales to ROW.

New developments

We are working on adapting ClearCoast™ for additional applications and cancer types beyond breast-conserving surgery.

Connect with ClearCut

Elevate your surgical precision and improve patient outcomes. Reach out to our team to learn more about the ClearCut system or to schedule a demonstration. We are here to answer your questions and support your mission.